Protocol Ledger

NCT07545759 · Phase II · RECRUITING

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

Interventional Phase II clinical trial protocol NCT07545759 sponsored by Eli Lilly and Company in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-06 Enrollment: 531 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07545759
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)531 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07545759
Protocol FieldVerified Registry Value
NCT IdentifierNCT07545759
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment531 participants (ESTIMATED)
Registered Start Date2026-05-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07545759
Hospital Research SiteLocationSite Profile
Om Research LLCLancaster, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI